临床实践中生物制剂治疗银屑病的完全清除与PASI应答率:预测因素、生活质量改善及治疗目标启示
该研究基于瑞典PsoReg注册数据,纳入515例首次使用生物制剂的银屑病患者,分析PASI百分比应答的预测因素及不同应答水平的生活质量改善。结果显示高PASI百分比应答与换药前绝对PASI较高和BMI较低相关;所有应答组DLQI和EQ-5D均显著改善;PASI 100组换药前绝对PASI较低且绝对改善较小。结论认为基于PASI百分比的相对指标不适用于临床指南或随访。
要点
- 换药前绝对PASI较高和BMI较低与更高的PASI百分比应答相关。
- 所有应答组DLQI和EQ-5D均显著改善,但改善幅度组间有差异。
- 基于PASI百分比的治疗目标不适用于临床实践中的指南或随访。
核心结论
- PASI百分比变化很大程度上取决于换药前绝对PASI值,PASI 90等相对目标不适用于临床指南或随访。
研究设计与样本
- 基于瑞典PsoReg注册的队列研究,纳入515例首次使用生物制剂的银屑病患者,分析换药前6个月内和换药后3-12个月的PASI、DLQI和EQ-5D数据。
主要发现
- 高PASI百分比应答与换药前较高PASI和较低BMI相关。
- 换药前PASI >30的患者中很少达到完全皮肤清除。
关键数值与推荐
- PASI 100组换药前绝对PASI较低,且绝对PASI和HRQoL改善低于接近清除的患者。
临床怎么用
- 临床实践中应关注绝对PASI值而非仅依赖PASI百分比应答来设定治疗目标和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis Area and Severity Index (PASI) 90 is suggested to be the new standard endpoint for randomized controlled trials of biologics for psoriasis, whereas treatment guidelines often still refer to PASI 75. OBJECTIVES: To analyse in a real-world setting: firstly, what factors are associated with higher levels of treatment response to biologics; secondly, the health-related quality of life gains associated with different response levels in clinical practice. METHODS: Biologically naïve patients with PASI, Dermatology Life Quality Index (DLQI) and EuroQol (EQ)-5D outcomes before (maximum 6 months) and after (3-12 months) switch to biologics during registration in the Swedish National Registry for Systemic Treatment of Psoriasis (PsoReg) were included (n = 515). Patient characteristics associated with higher treatment response were analysed by regression analyses. Improvements in absolute PASI, DLQI and EQ-5D were assessed in different PASI percentage response levels. RESULTS: High PASI percentage response was associated with higher PASI before switch and lower body mass index. DLQI and EQ-5D improved within all responder groups (P < 0·001). The magnitude of improvements in DLQI (P = 0·02) differed between responder groups. The mean (SD) DLQI improvements for PASI 75<90 responders, PASI 90<100 responders and patients achieving complete skin clearance (PASI 100) were 9·9 (7·4), 11·5 (7·0) and 8·0 (6·1), respectively. CONCLUSIONS: PASI percentage change is largely dependent on absolute PASI before switch. Patients in clinical practice lack 'baseline' PASI values as they may switch directly from one treatment to another or stay successfully treated for a longer time period. Treatment goals such as PASI 90 are thus not suitable for treatment guidelines or for follow-up in clinical practice. What's already known about this topic? Randomized clinical trials of biologics as well as treatment guidelines include treatment goals based on a percentage improvement compared with baseline Psoriasis Area and Severity Index (PASI), such as PASI 75 or PASI 90. Few studies have assessed which factors are associated with high skin clearance rates, or health-related quality of life (HRQoL) improvements associated with different levels of skin clearance in clinical practice. What does this study add? A high absolute PASI before switch to biologics and low body mass index are associated with higher PASI percentage response. Few patients with baseline PASI >30 achieved complete skin clearance (CSC). All responder groups achieved significant HRQoL improvements. Patients achieving CSC (PASI 100) had lower absolute PASI before switch and lower improvements in absolute PASI and HRQoL than patients with almost cleared skin. What are the clinical implications of this work? Relative measures based on PASI percentage, such as PASI 75 or PASI 90, are not suitable for treatment guidelines or for follow-up in clinical practice.
引用
- Norlin JM, Nilsson K, Persson U, et al. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals. Br J Dermatol. 2019. PMID: 31325318. doi:10.1111/bjd.18361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。